Take a spin on our BO pricing model!Our model is generating a range of $35-63 BO PPS, per the low/high case scenarios below - where only the Voc price is different (25k vs 50k). My hunch is that this is both conservative and in the ballpark. It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0. OutcomePatient Pool (Same for both Scenarios) Pricing: Price/Sales ratioHere's the Link to the model
Low end BO PPS w/30% discount: $35 ($50 no discount) High End BO PPS w/30% discount $63 ($90 no discount) Prev: 26.5 per 100,000 (Based on epidemiological study) Total Patient pool (US, Europe, Japan): 252,333 % of patients on treatment: 50% Total Patients on treatment: 88,317
Low: $25,000 (50% of Aurinia low end) High: $50,000 (100…
Voclosporin will likely be approved well before the P3 trial runs it course.
Here's how it's going to work. First, there's a legal and regulatory path for this approval. While I quote the relevant passage below, here's the link to the FDA Regulations, as well as alist of drugsthatreceived accelerated approval.
Sec. 314.510 Approval based on a surrogate endpoint or on an
effect on a clinical endpoint other than survival or irreversible morbidity. FDA may grant marketing approval for a new drug product on
the basis of adequate and well-controlled clinical trials establishing that the
drug product has an effect on a surrogate endpoint that is reasonably likely,
based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to
predict clinical benefit or on the basis of an effect on a clinical endpoint
other than survival or irreversible morbidity. Approval under this section will
be subject to the requirement that the applicant study the drug further, to
Yup. iHub can't get rid of "Biotech Researcher," aka BR. It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own.
So shame on iHub for not taking action to resolve this.
I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same.